Lacidipine CAS 103890-78-4 Glipizide CAS 29094-61-9 Fluvastatin CAS 93957-54-1 Antilipemic Agent Gemfibrozil CAS No 25812-30-0

China Lacidipine CAS 103890-78-4 Glipizide CAS 29094-61-9 Fluvastatin CAS 93957-54-1 Antilipemic Agent Gemfibrozil CAS No 25812-30-0, Find details about China Lacidipine CAS 103890-78-4, Glipizide CAS 29094-61-9 from Lacidipine CAS 103890-78-4 Glipizide CAS 29094-61-9 Fluvastatin CAS 93957-54-1 Antilipemic Agent Gemfibrozil CAS No 25812-30-0

Model NO.
Gemfibrozil
Mf
C15h22o3
MW
250.33
CAS
25812-30-0
Appearance
White Crystalline Powder
Function
Biological and Pharmaceutical Intermediates
Shelf Life
2 Years
Test Method
HPLC UV
Storage
Cool Dry Place
Payment
Tt.Western Union .Credit Card.Moneygram
Delivery Time
Within 2 Days
Certificate
COA MSDS
Sample
Available
Trademark
Faithful
Transport Package
Aluminum Foil Bag Packaging
Specification
10g/bag; 100g/bag; 1kg/bag
Origin
China
Model NO.
Gemfibrozil
Mf
C15h22o3
MW
250.33
CAS
25812-30-0
Appearance
White Crystalline Powder
Function
Biological and Pharmaceutical Intermediates
Shelf Life
2 Years
Test Method
HPLC UV
Storage
Cool Dry Place
Payment
Tt.Western Union .Credit Card.Moneygram
Delivery Time
Within 2 Days
Certificate
COA MSDS
Sample
Available
Trademark
Faithful
Transport Package
Aluminum Foil Bag Packaging
Specification
10g/bag; 100g/bag; 1kg/bag
Origin
China
Lacidipine CAS 103890-78-4 Glipizide CAS 29094-61-9 Fluvastatin CAS 93957-54-1 Antilipemic Agent Gemfibrozil CAS No 25812-30-0Lacidipine CAS 103890-78-4 Glipizide CAS 29094-61-9 fluvastatin CAS 93957-54-1  Antilipemic Agent Gemfibrozil CAS No 25812-30-0

Introduction

Gemfibrozil, 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid (Lopid), is a congener of clofibratethat was used first in the treatment of hyperlipoproteinemia inthe mid-1970s. Its mechanism of action and use are similar tothose of clofibrate. Gemfibrozil reduces plasma levels ofVLDL triglycerides and stimulates clearance of VLDL fromplasma. The drug has little effect on cholesterol plasma levelsbut does cause an increase of HDL.

Gemfibrozil is absorbed quickly from the gut and excretedunchanged in the urine. The drug has a plasma half-life of1.5 hours, but reduction of plasma VLDL concentration takesbetween 2 and 5 days to become evident. The peak effect of its hypolipidemic action may take up to 4 weeks to becomemanifest.
Application
1. Used for the treatment of hyperlipidemia. The agent is suitable for treatment of severe type IV or type V hyperlipoproteinemia patients with high-risk coronary heart disease who had no response to treatments such as dietary control or weight loss. It is also applicable to type II-b hyperlipoproteinemia patients with high-risk coronary heart disease who had failed to respond to treatments such as dietary control, weight loss, or other lipid-regulating medications.

2. Used as a lipid-regulating agent. It can significantly reduce the levels of triglyceride and cholesterol in blood, and can significantly reduce very low-density lipoprotein (VLDL) levels and increase high-density lipoprotein (HDL) levels, but it has little effect on low-density lipoprotein (LDL) levels. Clinically, it can be used in patients with all types of lipid metabolism disorders, such as primary and secondary hyperlipoproteinemias, hypercholesterolemias, hypertriglyceridemias, mixed hyperlipidemias, and lipid metabolism disorders caused by diabetes. It can also be used to prevent the occurrence of myocardial infarction.

3. The product belongs to phenoxy aromatic acid antihyperlipidemics, which is a group of drugs developed on the basis of clofibrate including fenofibrate, Etofylline Clofibrate, Bijiangzhi, gemfibrozil and so on. These drugs were similar in chemical structure. Clofibrate has rather serious adverse reactions (which include elevating the occurrence of gallstone). Improved drugs are more effective than clofibrate, with mild and fewer adverse reactions.

4. A lipid-regulating drug that can reduce cholesterol and triglyceride levels in blood.

 

Specification
 

ItemsStandardsResults
AppearanceWhite or off-white solid powderComplies
IdentificationBy IRComplies
By HPLCComplies
SolubilitySoluble in DMF, sparingly soluble in THF, slightly soluble in and acetonitrile, very sightly soluble in ethanol and dichloromethane, insoluble in water.Complies
Polymorphic FormPolymorphic form 1Complies
Melting Point211ºC~216ºC212.8ºC~214.9ºC
Water Content≤ 0.50%0.10%
Heavy Metals≤ 20ppmComplies
Residue on Ignition≤ 0.20%0.09%
Related SubstanceAny single impurity: ≤0.10%0.06%
Total Impurities: ≤1.00%0.16%
Assay                  
(on the anhydrous basis)
98.0%~102.0%99.94%
Particle SizeD90: ≤100µmComplies
Reference StandardIn-house Standard
ConclusionThe product complied to In-house standard.
StoragePreserve in tight,light-resistant containers in a cool place

 

Lacidipine CAS 103890-78-4 Glipizide CAS 29094-61-9 Fluvastatin CAS 93957-54-1 Antilipemic Agent Gemfibrozil CAS No 25812-30-0Lacidipine CAS 103890-78-4 Glipizide CAS 29094-61-9 Fluvastatin CAS 93957-54-1 Antilipemic Agent Gemfibrozil CAS No 25812-30-0Lacidipine CAS 103890-78-4 Glipizide CAS 29094-61-9 Fluvastatin CAS 93957-54-1 Antilipemic Agent Gemfibrozil CAS No 25812-30-0Lacidipine CAS 103890-78-4 Glipizide CAS 29094-61-9 Fluvastatin CAS 93957-54-1 Antilipemic Agent Gemfibrozil CAS No 25812-30-0Lacidipine CAS 103890-78-4 Glipizide CAS 29094-61-9 Fluvastatin CAS 93957-54-1 Antilipemic Agent Gemfibrozil CAS No 25812-30-0Lacidipine CAS 103890-78-4 Glipizide CAS 29094-61-9 Fluvastatin CAS 93957-54-1 Antilipemic Agent Gemfibrozil CAS No 25812-30-0Lacidipine CAS 103890-78-4 Glipizide CAS 29094-61-9 Fluvastatin CAS 93957-54-1 Antilipemic Agent Gemfibrozil CAS No 25812-30-0